November 2025’s Top Penny Stock Opportunities

Simply Wall St

Thu, November 27, 2025 at 1:04 PM EST 4 min read

As the U.S. stock market enjoys a promising streak with major indexes on track for their best week since June, investors are eyeing opportunities across various sectors. Penny stocks, though often seen as a niche area of investment, continue to capture attention due to their potential for growth in smaller or newer companies. While the term may seem outdated, these stocks can still offer intriguing prospects when backed by solid financials and strategic positioning in the current market landscape.

Click here to see the full list of 350 stocks from our US Penny Stocks screener.

Let’s explore several standout options from the results in the screener.

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing impactful medicines for epilepsies and seizure-related neurological disorders in the United States, with a market cap of $106.82 million.

Operations: The company generates revenue from its Pharmaceuticals segment, amounting to $6.61 million.

Market Cap: $106.82M

Ovid Therapeutics, a biopharmaceutical company with a market cap of US$106.82 million, remains unprofitable and is not expected to achieve profitability in the next three years. Despite this, it has shown revenue growth from US$0.49 million to US$6.53 million over nine months ending September 2025, primarily through its Pharmaceuticals segment. The company recently announced positive Phase 1 results for OV329, targeting drug-resistant epilepsies, potentially boosting future prospects. A CEO transition plan is underway with Meg Alexander set to assume leadership in January 2026. Ovid remains debt-free but faces high volatility and short cash runway challenges despite recent capital raises.

• Click here to discover the nuances of Ovid Therapeutics with our detailed analytical financial health report.

• Gain insights into Ovid Therapeutics’ future direction by reviewing our growth report.

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Cassava Sciences, Inc. is a clinical-stage biotechnology company focused on developing drugs for neurodegenerative diseases, with a market cap of approximately $146.86 million.